Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Bone Neoplasms × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 44 Carcinoma, Renal Cell 25 Neoplasm Metastasis 15 Neoplasms 13 Kidney Neoplasms 11 Neuroendocrine Tumors 10 Carcinoma, Neuroendocrine 9 Prostatic Neoplasms 7 Thyroid Neoplasms 6 Sarcoma 6 Meningioma 6 Melanoma 6 Lymphoma 6 Tuberous Sclerosis 5 Recurrence 5 Lymphoma, Mantle-Cell 5 Head and Neck Neoplasms 5 Endometrial Neoplasms 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Glioma 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Astrocytoma 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Neurofibromatosis 2 3

Interventions

Gemcitabine 5 Nivolumab 3 Irinotecan 3 Ipilimumab 3 Docetaxel 3 Cyclophosphamide 3 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3 pegfilgrastim 2 Vincristine 2 Temozolomide 2 Ibandronic Acid 2 Doxorubicin 2 CTLA-4 Antigen 2 spartalizumab 1 samarium Sm-153 lexidronam 1 pembrolizumab 1 palbociclib 1 liposomal doxorubicin 1 fludarabine 1 anlotinib 1 angiotensin I (1-7) 1 aldesleukin 1 Trabectedin 1 Topotecan 1 Taxes 1 Sunitinib 1 Samarium 1 Radiosurgery 1 Radiation 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01830153 2013-04-12

RAD001 in Advanced Sarcoma

Asan Medical Center

Phase 2 Completed

Bone Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡